Showing results (1-10 of 549) with videos related to
Sort By:
Pageof 55
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 16, 2007
[International clinical trials for a medical oncologist in Japan]Kazuhiko NakagawaNihon Rinsho. Japanese Journal of Clinical Medicine|August 19, 2015
[Novel signal transduction pathways: the molecular basis for targeted cancer therapies in Hedgehog/Notch/Wnt pathway]Toshio Shimizu, Kazuhiko NakagawaCancer Science|May 10, 2012
Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspectsIsamu Okamoto, Kazuhiko NakagawaCurrent Cancer Drug Targets|November 17, 2015
Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung CancerMasayuki Takeda, Kazuhiko NakagawaMolecular and Clinical Oncology|January 27, 2017
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancerMasayuki Takeda, Kazuhiko NakagawaJapanese Journal of Clinical Oncology|June 16, 2012
Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancerTakayasu Kurata, Kazuhiko NakagawaInternational Journal of Molecular Sciences|January 6, 2019
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer?Masayuki Takeda, Kazuhiko NakagawaGan to Kagaku Ryoho. Cancer & Chemotherapy|July 8, 2022
[The Achievements for"7-University Joint Project of Training Plan for Oncology Professionals]Kazuya Fukuoka, Kazuhiko NakagawaNihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Molecular targeted therapy in lung cancer]Koichi Azuma, Kazuhiko NakagawaInternational Journal of Clinical Oncology|September 25, 2019
Combination therapy with PD-1 or PD-L1 inhibitors for cancerHidetoshi Hayashi, Kazuhiko NakagawaPageof 55